Browse by author
Lookup NU author(s): Dr Sonja Baumli
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
Author(s): Krystof V, Baumli S, Furst R
Publication type: Review
Publication status: Published
Journal: Current Pharmaceutical Design
Print publication date: 01/07/2012
ISSN (print): 1381-6128
ISSN (electronic): 1873-4286
Publisher: BENTHAM SCIENCE PUBL LTD